Can Cefixime Be Given to a 1-Year-Old?
Yes, cefixime can be safely given to a 1-year-old child, as the FDA label explicitly states that safety and effectiveness have been established in children aged 6 months and older 1.
FDA-Approved Age Range
The FDA drug label clearly indicates that cefixime is approved for pediatric patients 6 months of age and older 1. Since your patient is 1 year old, they fall well within the approved age range. Safety and effectiveness in children younger than 6 months have not been established, but this is not a concern for your 1-year-old patient 1.
Clinical Evidence Supporting Use in This Age Group
Multiple clinical studies have demonstrated both safety and efficacy of cefixime in young children:
Pharmacokinetic studies in infants and young children aged 2-22 months (mean age 9.5 months) showed appropriate drug levels with an 8 mg/kg dose, with peak serum concentrations occurring at 2-8 hours and elimination half-life of 2.6-5.6 hours 2.
Clinical trials in children as young as 0.5 months (though FDA approval is for ≥6 months) demonstrated a 93% overall cure and improvement rate for various infections including otitis media, enterocolitis, and urinary tract infections 3.
A landmark randomized trial in 306 children aged 1-24 months with febrile urinary tract infections showed oral cefixime was equally effective as initial intravenous cefotaxime, with comparable rates of urine sterilization, defervescence, and renal scarring at 6 months 4.
Approved Indications in Pediatrics
For your 1-year-old patient, cefixime is FDA-approved for 1:
- Uncomplicated urinary tract infections
- Otitis media
- Pharyngitis and tonsillitis
Dosing Considerations
The typical pediatric dose is 8 mg/kg/day, which can be given as a single daily dose or divided into two doses 2. The suspension formulation is preferred for this age group and produces 25-50% higher peak concentrations than tablets 1.
Safety Profile
The FDA label notes that gastrointestinal adverse reactions (diarrhea, loose stools) in pediatric patients receiving suspension were comparable to those in adults receiving tablets 1. In clinical studies of young children, mild transient diarrhea occurred in some patients, but no significant adverse reactions were observed 3.